Seeking Alpha

Can-Fite Dry-Eye therapy fails in Phase III

  • Can-Fite BioPharma's (CANF) CF101 therapy didn't achieve its primary endpoint in a Phase III study of 237 patients with moderate-to-severe Dry Eye Syndrome.
  • The drug failed to completely clear corneal staining, nor did it meet secondary endpoints.
  • Still, Can-Fite is also developing CF101 for treating Glaucoma and Uveitis, with interim data from a phase II study for Glaucoma expected to be released during 2014. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector